What is the appropriate evaluation for a patient with a family history of hereditary hemochromatosis?

Evaluation of Patients with Family History of Hereditary Hemochromatosis

Adult first-degree relatives of patients with hereditary hemochromatosis should undergo simultaneous genetic testing (HFE mutation analysis) and biochemical screening (transferrin saturation and serum ferritin) at a single visit. This dual approach provides both genotype and phenotype information efficiently and is the recommended standard of care 1, 2.

Initial Testing Strategy

For adult first-degree relatives (parents, siblings, children) of a confirmed hemochromatosis patient:

Step 1: Simultaneous Testing

• HFE genetic testing for C282Y and H63D mutations
• Transferrin saturation (TS)
• Serum ferritin

This simultaneous approach is explicitly recommended by both the 2022 EASL guidelines (100% consensus) 1 and the 2011 AASLD guidelines 2, as it allows for complete assessment in a single visit and avoids delays in diagnosis.

Step 2: Interpretation Based on Results

If C282Y homozygous (C282Y/C282Y) is found:

• If ferritin is elevated: initiate therapeutic phlebotomy 2
• If ferritin is normal: yearly follow-up with iron studies 2

If compound heterozygous (C282Y/H63D) is found:

• If ferritin elevated: consider phlebotomy based on individualized clinical assessment 1
• Monitor for other causes of iron overload 1

If C282Y heterozygote or H63D heterozygote:

• Reassure the patient—these individuals are not at risk for developing progressive or symptomatic iron overload 2
• No further routine monitoring needed

If H63D homozygous:

• Generally not at risk of progressive iron overload 2
• Occasional mild iron overload possible, but management guided by phenotype, not genotype 1

Special Consideration for Children

For children of a confirmed hemochromatosis patient:

• Test the other parent first with HFE genetic testing 2
• If the other parent is normal (no C282Y mutation), the child is an obligate heterozygote
• No further testing needed for the child, as there is no increased risk of iron loading 2
• Genetic testing can be offered after age 18 3

Biochemical Thresholds to Remember

Abnormal values suggesting hemochromatosis:

• TS ≥ 45% (for both men and women) 2
• Ferritin > 300 μg/L in men 1
• Ferritin > 200 μg/L in women 1

Common Pitfalls to Avoid

1. Don't rely on biochemical testing alone in family screening—genetic testing provides definitive information about risk and should be done simultaneously 2

2. Don't over-interpret H63D mutations—H63D heterozygotes and even most H63D homozygotes do not develop clinically significant iron overload 2

3. Don't forget cofactors—even heterozygotes can develop liver disease when combined with other conditions like hepatitis C, alcohol-related liver disease, or NAFLD 2

4. Don't screen children unnecessarily—if one parent is confirmed normal, children are obligate heterozygotes and don't need testing 2

Why This Approach Matters for Outcomes

Early detection through family screening is critical because:

• Approximately 30% of new hemochromatosis cases are detected through family screening 4
• Treatment with phlebotomy before organ damage occurs can prevent all manifestations of the disease 5
• Once diagnosed early, patients have an excellent prognosis with simple phlebotomy treatment 6
• Liver damage, endocrine dysfunction, and arthropathy are often irreversible if diagnosis is delayed 5

The simultaneous genetic and biochemical testing approach maximizes detection while minimizing unnecessary follow-up visits, addressing the documented problem that only 13% of at-risk families achieve complete screening 4.